Аннотации:
Due to the constant increase in morbidity and mortality, bladder cancer remains apressing problem in modern medicine. Despite the success of chemotherapy, chemotherapy physicians around the world have been concerned about the safety ofthese drugs for many years. Doxorubicin has been used as an antitumor drug for morethan 40 years in various hematological and solid malignancies, however, its toxiceffects when administered intravenously to vital organs and organ systems, includingthe heart, require further research. The aim of our study was to evaluate the manifestationsand progression of cardiotoxicity in patients with bladder cancer with systemic and intravesical administration of doxorubicin. The study included 96 patients who weredivided into three groups: the first group or the control group - patients who had aconfirmed diagnosis of first stage bladder cancer, were treated surgically and did notreceive doxorubicin; the second group - patients who, in addition to surgical treatment, received doxorubicin systemically (intravenously) in a therapeutic dose; the third group- patients who received doxorubicin at a dose of 50 mg, locally, by instillation of thedrug into the bladder cavity, after prior catheterization with an elastic catheter. ECGdata and biochemical markers of myocardial destruction before and after chemotherapywere studied. The study found that systemic serial administration of doxorubicin to patients with bladder cancer causes significant changes in the myocardium after thefirst course of chemotherapy. A single intravesical instillation of doxorubicin does notcause changes in laboratory and instrumental heart rate.
